Eli Lilly just debuted its powerful new weight-loss drug, Zepbound.
Normally, when newer, better drugs are introduced, they match the price of similar drugs already available or come at a premium .
Eli Lilly and Novo Nordisk have said that about 50 million people have some level of insurance coverage for weight-loss drugs.
But some experts were skeptical, because employers and insurers don't typically pay the list price for drugs.
Craig Garthwaite, an economist at Northwestern University, argued competition will drive the net prices of weight-loss drugs lower still.
Persons:
Eli Lilly, —, Wegovy, LLY, It's, Mike Mason, coinsurance, Antonio Ciaccia, Crystal, We're, David Risinger, Dave Ricks, David Ricks, Eli Lilly's Mason, Mason, Craig Garthwaite, Garthwaite
Organizations:
Service, pharma, Nordisk's Wegovy, Ozempic, Deutsche Bank, 46brooklyn Research, Crystal Cox, Novo Nordisk, Zepbound, Wegovy, American Enterprise Institute, Northwestern University
Locations:
Mounjaro